This article discusses the key eligibility criteria for participating in Nivolumab clinical trials. It highlights the necessary health conditions, age restrictions, and other critical factors that determine suitability for these immunotherapy studies sponsored by the U.S. NIH. Understanding these criteria helps potential candidates assess their eligibility and prepare for participation in cutting-edge cancer research.

Eligibility Criteria for Participating in Nivolumab Clinical Trials

Nivolumab, a monoclonal antibody designed for immunotherapy, is used to treat various cancers. Conducted by the U.S. National Institutes of Health, these clinical trials assess its safety and effectiveness. Criteria for participation vary based on specific studies, but generally, patients must meet certain health and demographic requirements to ensure valid outcomes and safety.

Individuals aged 18 years or older who can provide independent consent are eligible; minors require parental approval.

Must have a confirmed diagnosis of the relevant cancer, including relapsed or previously treated cases, or be classified as high risk based on the International Prognostic Scoring System (IPSS).

Volunteers should sign an IRB-approved informed consent document.

Patients with prior immune checkpoint inhibitor therapy are typically not suitable.

They should not have other active cancer types.

Must meet ECOG performance status standards to qualify.

Women must be non-pregnant and agree to use contraception during the study.

Organ function tests, including blood counts and kidney function, should be within normal limits.

Recent chemotherapy (within four weeks) might disqualify applicants.